Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Theregen, Inc.
Tech Transfer Deals, July 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June.
The New World Of Device Venture Investing: Same As The Old World?
At Elsevier Business Intelligence's February IN3 West conference, a panel of leading device venture investors, who remain committed to and are actively doing deals in medtech, discussed how the recent recession has affected device investing and how much, if at all, that world has changed as a result.
Succeeding in Heart Failure, Incrementally
Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.
Theregen Corp.'s Anginera is a cell-based epicardial patch designed to promote blood vessel growth in ischemic cardiac tissue. Numerous animal studies have demonstrated that Anginera-which is based on the Dermagraft wound repair patch--promotes angiogenesis and arteriogenesis in ischemic tissue, and may also preserve or repair cardiac function in the failing heart.
- Gene Therapy, Cell Therapy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.